# Kiniksa Pharmaceuticals International, plc (KNSA) FY2026 Q3 Revenue by Business Segment by Geography

- Company: Kiniksa Pharmaceuticals International, plc (KNSA)
- Statement: Kiniksa Pharmaceuticals International, plc (KNSA) FY2026 Q3 P&L / Income Statement, https://plicit.ai/financials/knsa/fy2026-q3-income-statement
- Period: 2026-07-01 to 2026-09-30
- Filing: Q3 FY2026 10-Q, filed 2026-10-27, accession number 0001104659-26-119186
- Page: https://plicit.ai/financials/knsa/fy2026-q3-income-statement/revenue-by-business-segment-by-geography
- Chart image: https://plicit.ai/charts/knsa-fy2026-q3-revenue-by-business-segment-by-geography-sankey.png

## Chart details: Revenue by Business Segment by Geography

Income statement for 2026-07-01 through 2026-09-30. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 285,970,000 US dollars
- **Operating expenses (calculated)**: 231,734,000 US dollars
- **Income from operations**: 54,236,000 US dollars
- **Other income (expense), net (calculated)**: 4,821,000 US dollars
- **Income before income taxes**: 59,057,000 US dollars
- **Provision for income taxes**: 11,712,000 US dollars
- **Net income**: 47,345,000 US dollars
- **Pharmaceutical - UNITED KINGDOM**: 243,000 US dollars
- **Pharmaceutical - UNITED STATES**: 285,727,000 US dollars
- **Total operating expenses**: 231,734,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
